Molnupiravir: All you need to know about the oral anti-Covid pill

  • Approved for use in the UK, likely to get nod in India soon
  • First oral medicine in the world to be approved for use against Covid
  • Developed by the pharmaceutical companies Ridgeback Biotherapeutics and Merck, Sharp and Dohme
  • The antiviral drug molnupiravir was originally developed to treat the flu
  • Meant for adults at risk for progressing to severe Covid or hospitalisation
  • To be given to patients within 5 days of symptoms appearing
  • Will be given twice a day to patients recently diagnosed with Covid
  • Molnupiravir works by disrupting the virus’s reproduction.
  • Reduces the risk of hospitalisation or Covid death by 50%
  • Ineffective if it’s taken after the patient is hospitalised
  • The treatment can be given to both vaccinated and unvaccinated patients

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store